clofibric acid has been researched along with Fatty Liver in 5 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dyslipidemia in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis may improve with use of statins, fibrates, niacin, and thiazolidinediones, but the data are presently very limited." | 4.82 | Management of dyslipidemia in patients with complicated metabolic syndrome. ( Davidson, MH, 2005) |
| "Fenofibrate treatment decreased hepatic macrophage accumulation and abolished steatosis." | 1.33 | Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. ( Buffat, L; Gijbels, MJ; Hofker, MH; Maeda, N; Noel, B; Shiri-Sverdlov, R; Staels, B; van Bilsen, M; van Gorp, PJ; Wouters, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karahashi, M | 1 |
| Hoshina, M | 1 |
| Yamazaki, T | 1 |
| Sakamoto, T | 1 |
| Mitsumoto, A | 1 |
| Kawashima, Y | 1 |
| Kudo, N | 1 |
| Hwang, B | 1 |
| Wu, P | 1 |
| Harris, RA | 1 |
| Davidson, MH | 1 |
| Shiri-Sverdlov, R | 1 |
| Wouters, K | 1 |
| van Gorp, PJ | 1 |
| Gijbels, MJ | 1 |
| Noel, B | 1 |
| Buffat, L | 1 |
| Staels, B | 1 |
| Maeda, N | 1 |
| van Bilsen, M | 1 |
| Hofker, MH | 1 |
| Miyazawa, S | 1 |
| Furuta, S | 1 |
| Hashimoto, T | 1 |
1 review available for clofibric acid and Fatty Liver
| Article | Year |
|---|---|
Management of dyslipidemia in patients with complicated metabolic syndrome.
Topics: Clofibric Acid; Fatty Liver; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-Co | 2005 |
4 other studies available for clofibric acid and Fatty Liver
| Article | Year |
|---|---|
Fibrates reduce triacylglycerol content by upregulating adipose triglyceride lipase in the liver of rats.
Topics: Animals; Bezafibrate; Clofibric Acid; Fatty Liver; Fenofibrate; Lipase; Lipid Peroxidation; Liver; M | 2013 |
Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet.
Topics: Animals; Clofibric Acid; Diet, High-Fat; Fatty Liver; Hypolipidemic Agents; Isoenzymes; Mice; Mice, | 2012 |
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; ATP-Binding Cassette Transporters; Clofibric Acid; Di | 2006 |
Reduction of beta-oxidation capacity of rat liver mitochondria by feeding orotic acid.
Topics: Acyl-CoA Dehydrogenases; Adenine; Animals; Clofibric Acid; Diet; Fatty Acids; Fatty Liver; Male; Mit | 1982 |